{"name":"BioCorRx Inc","slug":"biocorrx-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":7665,"revenueGrowth":-91.4,"grossMargin":0,"rdSpend":1482877,"netIncome":-5212102,"cash":385941,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2018-01-01","label":"Lucemyra first approved","drug":"Lucemyra","drugSlug":"lofexidine","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Lucemyra","genericName":"LOFEXIDINE","slug":"lofexidine","indication":"Opioid withdrawal","status":"marketed"}]}],"pipeline":[{"name":"Lucemyra","genericName":"LOFEXIDINE","slug":"lofexidine","phase":"marketed","mechanism":"Lucemyra works by activating the alpha-2A adrenergic receptor to reduce the release of norepinephrine, a neurotransmitter involved in withdrawal symptoms.","indications":["Opioid withdrawal"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQUU05dDRSSW1PRk5jZWZRbXVyUW8yY19OQWNRa2Z6NGEyWGQ1NV9DY3lnTDhvTzRIcVJkaFRudzN1Z01jdHJTMHNERmpFTm9QamF5bDB0TTVlYi02VWNWSDR0VVR1VUN3LWh1VE5xdG1JTnEtMVdnV3I5T09KazRYVzBmSC1lZWJYWFhNNnlObjJPRTJNSURvX1NnYmtrSFJXb0NTcWxB?oc=5","date":"2026-04-02","type":"pipeline","source":"Stock Titan","summary":"BioCorRx (BICX) issues 2.26M shares in insider stock exchange - Stock Titan","headline":"BioCorRx (BICX) issues 2.26M shares in insider stock exchange","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOZ3RObjVoVkVZSGJmOXlRMHo4aHkwdzhTeXR2TkJad1Y4UFZMY0RIYkNCRFRueWtYbnR2VGRpS2NDeEFrdjRuSExtZUJ3a0pKT1Mtck4ySlBBV2pXY0ZmaXo0dndjdFFQcFVSUks1a2E2NFdYTDFUcjd0dkFia2g0TWtWS1plSzN5dVI1N0JVcEJxQ1JTc1pINHdDcnJ6ekQ1SDF4Rjd5elNjN09yYmZ3UUdR?oc=5","date":"2026-04-02","type":"deal","source":"TipRanks","summary":"BioCorRx Reorganizes Subsidiary Through Equity Exchange Deal - TipRanks","headline":"BioCorRx Reorganizes Subsidiary Through Equity Exchange Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQUEs1d0QzamN0UEsxeWlJMWE0aFJlX1VZQnNiOTdFd1Rkdlk0SjBOZ2JZQzRzUlJkNHgzdkNMa2JFdkhwQWtvVGdvY2U4SlhWYmlHVVpONFRPMDNCTmw5VFBkaG1OSGEtN1p5NHJQZXBOazZpekZBY3kxMEE3dGdMTFdyY0ZzTVdidnYtejZSTzZncklOLWNyU0ZHd0UwVHdJMm8wT2ZfMlFvQ2ZLZ3FZeEcxRzJudmpMVGRoV0ZMcm14QjI5aXVhOFFobzE3NDVNMHRoN0hRZmxjdmtJckE?oc=5","date":"2026-04-02","type":"deal","source":"TradingView","summary":"BioCorRx Swaps 2.26M Shares to Acquire 12.15% of Subsidiary, Advancing Tax-Free Reorg - TradingView","headline":"BioCorRx Swaps 2.26M Shares to Acquire 12.15% of Subsidiary, Advancing Tax-Free Reorg","sentiment":"neutral"},{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPSFVzaWVSUmJPVkxRRVk2WWczbVk4OGFDdFBwRXdIWUZpdmIzOW9fbXB0VmtsTXpRdjFac213aDNtRmF6YkkyWHVFbWNCYTlvSlZsZ3cxSTBaRjNlNmpybk5SSVlfemNwUmc0X2VEWjI1ZDlkd3VseS0zTUJXbEYzR1E2TEFRWGhsaXRtS216ZWxNSHhMaUhDcWJPZXB3T3laSzdaLXh6WjZxSXZaRlpMSjJB?oc=5","date":"2026-03-05","type":"trial","source":"Benzinga","summary":"BioXcel Therapeutics Stock Rallies Opioid Study Success - Benzinga","headline":"BioXcel Therapeutics Stock Rallies Opioid Study Success","sentiment":"positive"},{"date":"2025-11-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-08-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-08-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-05-15","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9tdWlRQktuUHlnQUhTM1ZpUDB6djVMbUVYaThua3RVNkRsaDNQeW5fV0RXVXZNdkZjVm9KcUYtYjdIamtfbkctaHVQVlVfSHRJeFQw?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"BICX Stock Price, News & Analysis - Stock Titan","headline":"BICX Stock Price, News & Analysis","sentiment":"neutral"},{"date":"2025-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2025-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2024-11-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2024-08-13","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":7665,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":7665,"period":"2024-12-31"},{"value":89160,"period":"2023-12-31"},{"value":89160,"period":"2023-12-31"},{"value":213841,"period":"2022-12-31"},{"value":213841,"period":"2022-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":1482877,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-5212102,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":385941,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}